SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing heightened market activity following a high-profile White House quantum policy event and the launch of a new quantum-focused space initiative, driving active community debate over potential government-backed growth versus volatility. Traders are closely monitoring the stock's technical levels, upcoming technical webinars, and its pending inclusion in the Russell index, all of which are fueling speculation about a breakout.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently facing intense selling pressure, with the stock sliding toward 52-week lows amid a broader cooling of software sector valuations. Investors are actively debating whether this is a structural breakdown or a temporary sentiment reset, with many highlighting the tension between the company's strong revenue growth and concerns over its high valuation multiples.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to the company's roadmap for gate-model quantum simulators and potential expansion into government-backed quantum initiatives. The community remains highly polarized, with intense debate between long-term bulls betting on quantum supremacy and skeptics focused on high cash burn, heavy insider selling, and extreme valuation concerns.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors debate the impact of leadership changes, including the upcoming departure of the CFO, while closely monitoring progress in the company's oncology pipeline following recent trial updates. Market participants are actively discussing the stock's long-term valuation and the effectiveness of current growth strategies in the competitive biotech landscape.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is drawing significant investor interest as shareholders bet on a long-term turnaround fueled by international expansion, a new CEO, and persistent buyout speculation involving major stakeholders. The community remains heavily focused on the stock's elevated short interest, with many retail traders actively discussing the potential for a short squeeze despite ongoing concerns regarding operational efficiency and food quality.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending following a significant clinical milestone, with investors closely watching its progress in late-stage trials for psychiatric disorders. Community sentiment is currently polarized, featuring both optimistic retail investors anticipating upcoming clinical data and vocal skeptics who are raising concerns about long-term financial dilution.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting significant retail and institutional interest as investors track substantial share accumulation by CEO Kevin Tang and speculate on a potential buyout. While the company maintains clinical progress and steady commercial performance, the community remains divided, weighing the upside of recent insider activity against long-standing frustration over management transparency and sluggish price movement.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing significant selling pressure, pushing shares to new lows and sparking a heated debate between traders who view the stock as deeply oversold value and those who argue that fading content momentum and weak sentiment justify further downside. The community is focused on the lack of stabilization at key technical support levels, with many traders expressing frustration over executive performance and the absence of aggressive share buybacks despite massive authorized capital.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is seeing intense investor attention and increased trade volume following a significant purchase order for its NeuraWave photonic reservoir systems and broader sector momentum surrounding government-led quantum technology initiatives. The community remains highly focused on the company's hardware commercialization progress and the potential for a short squeeze, given the substantial short interest and heavy call option activity.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending due to the convergence of an upcoming earnings report and the high-profile IPO of its partner Cerebras, sparking investor interest in its specialized data center and AI compute infrastructure model. The community is actively discussing the stock's low float and the potential for a valuation re-rate as it aligns with broader AI capacity demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What is HC Wainwright's Forecast for BBOT FY2026 Earnings?

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Free Report) - HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of BridgeBio Oncology Therapeutics in a report issued...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 52-Week Low - Here's What Happened

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sets New 52-Week Low - Here's Why...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Up 4.9% - Here's What Happened

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Up 4.9% - Still a Buy...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 5.8%  - Should You Sell?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 5.8% - What's Next...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sees Large Volume Increase  - Still a Buy?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sees Strong Trading Volume - Time to Buy...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 6.8% - What's Next?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 6.8% - Time to Sell...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 12-Month Low - Should You Sell?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 12-Month Low - Here's What Happened...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 1.3%  - Should You Sell?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 1.3% - Should You Sell...

BridgeBio Oncology (BBOT) Spotlights Next-Gen RAS Pipeline, $425M Cash Runway Into 2028

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) used a presentation at Leerink Partners' Global Healthcare Conference to outline its strategy around next-generation RAS therapeutics, highlighting three...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Issues Quarterly Earnings Results

BridgeBio Oncology Therapeutics (NASDAQ:BBOT - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.49) EPS for the quarter, topping analysts' consensus...

Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.

BridgeBio Oncology Therapeutics Inc.

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.56	--	--	N/A
Q1 '26	-$0.51	-$0.53	-2.76%	MISSED
Q4 '25	-$0.63	-$0.49	22.60%	BEAT
Q3 '25	-$0.38	-$1.03	-169.87%	MISSED
Q2 '25	-$38.51	-$49.62	-28.84%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBOTBridgeBio Oncology Therapeutics Inc.

Upcoming Earnings: Q2 '26

Historical Earnings

Latest BBOT News